Valneva ( (VALN) ) just unveiled an announcement.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Valneva has entered into a significant collaboration with the Serum Institute of India (SII) to expand the reach of its single-shot chikungunya vaccine in Asia amidst a severe outbreak in India. This exclusive license agreement will allow broader access to the vaccine, particularly in low-and-middle-income countries, backed by a $41.3 million funding agreement with CEPI and the European Union. The partnership will involve a technology transfer for the vaccine’s manufacturing process, with SII completing manufacturing and handling regulatory approvals in Asia. The vaccine’s commercialization will operate on a profit-sharing model, with Valneva receiving milestone payments. This initiative not only aims to address urgent public health needs but also enhances regional health security by ensuring affordable access to necessary doses, potentially mitigating the impact of the chikungunya virus in Asia and beyond.
More about Valneva
Valneva is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases that address unmet medical needs. The company is known for its highly specialized and targeted approach, advancing multiple vaccines from early research and development to approvals. Valneva currently markets three proprietary travel vaccines, including the world’s first and only licensed chikungunya vaccine, and is working on vaccine candidates for diseases such as Lyme disease, Zika virus, and Shigella.
YTD Price Performance: -64.21%
Average Trading Volume: 23,295
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $308.3M
For an in-depth examination of VALN stock, go to TipRanks’ Stock Analysis page.
